

Product Datasheet

Rezatapopt

Catalog No. **BP-02038** · CAS **2636846-41-6** · Form **free base** · Physical state **other** · Color **Off-white to yellow** · Version **1.0** · Revision **2026-09-02**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target MDM-2/p53	Research area Cancer
----------------------------	--------------------------------

Molecular formula **C₂₈H₃₁F₄N₅O₂**

Molecular weight **545.5717**

STRUCTURE



DESCRIPTION

Rezatapopt (PC14586) is an antineoplastic agent, used to inhibit solid tumor with p53 mutation.

BIOLOGICAL ACTIVITY

In Vivo

Rezatapopt induces complete regression of tumors in mice and potentiated checkpoint therapy.

SOLUBILITY

Soluble in DMSO : 50 mg/mL

REFERENCES

- [1]. Li Sujing, et al. Heteroarylalkyne compounds for targeting mutant of p53 and their preparation. World Intellectual Property Organization, WO2023016434 A1. 2023-02-16.
- [2]. Vu BT, et al. Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development. ACS Med Chem Lett. 2024 Nov 4;16(1):34-39.
- [3]. Spiegelberg D, et al. Targeting mutant p53: Evaluation of novel anti-p53R175H monoclonal antibodies as diagnostic tools. Sci Rep. 2025 Jan 6;15(1):1000.
- [4]. Schram A M, et al. 691TiP PYNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation[J]. Annals of oncology, 2024, 35: S535-S536.